2020
Consolidation Therapy in Primary Central Nervous System Lymphoma
Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyCentral nervous system lymphomaLong-term remissionNervous system lymphomaConsolidation therapyInduction therapyPerformance statusTransplant candidatesSystem lymphomaOpinion statementPrimary central nervous system lymphomaPrimary central nervous system lymphomaAutologous stem cell transplantTransplant-related mortality riskAdequate organ functionFavorable performance statusInitial induction therapyECOG performance statusHigh-dose cytarabineHigh-dose methotrexateHigh-dose chemotherapyStem cell transplantEnd of inductionHigh response rateCurative intentMyeloablative regimenPhase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.Peer-Reviewed Original ResearchConceptsRecurrent malignant gliomaDose-limiting toxicityMTOR inhibitor temsirolimusMalignant gliomasAkt inhibitor perifosinePhase I clinical trialDose level 3Dose level 7Phase II doseSynergistic anti-tumor effectKarnofsky performance statusPhase I trialDeadly primary brain cancerPI3K/Akt/mTOR axisPrimary brain cancerAkt/mTOR axisAnti-tumor effectsPotential therapeutic targetMost malignant gliomasPrior therapyTemsirolimus dosePerformance statusI trialIntracerebral hemorrhageCombined therapy
2017
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma
Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: 797-804. PMID: 28870792, PMCID: PMC5654655, DOI: 10.1016/j.ijrobp.2017.06.2466.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAstrocytomaBevacizumabBrainBrain NeoplasmsFemaleGlioblastomaHumansIntention to Treat AnalysisKarnofsky Performance StatusMaleMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, LocalOrgans at RiskProspective StudiesRadiation Dose HypofractionationRadiosurgeryRe-IrradiationTumor BurdenConceptsRecurrent high-grade gliomaDose-limiting toxicityHigh-grade gliomasStereotactic reirradiationHypofractionated Stereotactic Radiation TherapyCorpus callosum involvementDose level cohortsGrade 3 fatigueMedian overall survivalKarnofsky performance statusDose-escalation studyTreatment-related effectsBiological equivalent doseStereotactic radiation therapyWarrants further investigationAbsence of brainstemDose-escalation trial designBevacizumab dosesCallosum involvementConcomitant bevacizumabSymptomatic radionecrosisEscalation studyOverall survivalPerformance statusResected specimens
2013
Primary leptomeningeal lymphoma
Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, DeAngelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma. Neurology 2013, 81: 1690-1696. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.Peer-Reviewed Original ResearchConceptsPrimary leptomeningeal lymphomaPrimary CNS lymphomaLeptomeningeal lymphomaCNS lymphomaLeptomeningeal enhancementCSF cytologyMedian Eastern Cooperative Oncology Group performance statusRare formEastern Cooperative Oncology Group performance statusInternational Primary CNS Lymphoma Collaborative GroupIntra-CSF chemotherapyMedian overall survivalFavorable clinical responseCases of lymphomaOptimal diagnostic evaluationGene rearrangement studiesB-cell lymphomaMultifocal symptomsSalvage treatmentSystemic chemotherapyClinical responseOverall survivalPerformance statusMedian ageSystemic involvement
2012
First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis
Kasenda B, Ferreri A, Maturano E, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Xuan K, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Gloy V, Bhatnagar N, Haug S, Rahner S, Illerhaus G, Briel M. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. Blood 2012, 120: 3655. DOI: 10.1182/blood.v120.21.3655.3655.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaIndividual patient dataCentral nervous system lymphomaElderly PCNSL patientsMedian age 68Improved overall survivalFirst-line treatmentNervous system lymphomaOverall survivalElderly patientsPCNSL patientsSystematic reviewEligible studiesPerformance statusSystem lymphomaFunctional statusAge 68Patient dataBetter outcomesIndividual Patient Data Meta-AnalysisDifferent first-line treatmentsMultivariable Cox regression modelsFollowing baseline characteristicsImmunocompetent PCNSL patientsCo-morbidity index
2008
Primary CNS lymphoma with intraocular involvement
Grimm S, McCannel C, Omuro A, Ferreri A, Blay J, Neuwelt E, Siegal T, Batchelor T, Jahnke K, Shenkier T, Hall A, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto F, Abrey L. Primary CNS lymphoma with intraocular involvement. Neurology 2008, 71: 1355-1360. PMID: 18936428, PMCID: PMC4109164, DOI: 10.1212/01.wnl.0000327672.04729.8c.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaOverall survivalOcular therapyIntraocular involvementCNS lymphomaCSF cytologyMedian Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusMedian progression-free survivalClinical ophthalmic examinationLocal ocular therapyCommon presenting symptomProgression-free survivalSite of progressionDiagnosis of lymphomaEyes 12Primary CNSFree survivalIntraocular lymphomaPresenting symptomBrain lymphomaImmunocompetent patientsOcular involvementPerformance statusRetinal biopsy
2007
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsensusEye NeoplasmsFemaleHIV SeronegativityHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPrimary intraocular lymphomaOverall survivalMedian timeFocal therapyPrimary central nervous system lymphomaMedian ECOG performance statusCentral nervous system lymphomaTreatment typeECOG performance statusPositive CSF cytologyNervous system lymphomaBrain relapseMedian PFSMedian progressionPIOL patientsUncommon subsetIntraocular lymphomaPerformance statusRelapse patternsRetinal biopsyTreatment toxicityMedian ageSystem lymphomaInitial treatmentCSF cytology
2004
Brain metastases
Omuro AM, Abrey LE. Brain metastases. Current Neurology And Neuroscience Reports 2004, 4: 205-210. PMID: 15102346, DOI: 10.1007/s11910-004-0040-6.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyBrain metastasesBrain radiotherapyPerformance statusPoor prognosisSystemic diseaseFocal therapyAggressive focal therapiesGood performance statusImportant prognostic factorTreatment of recurrenceLong-term survivorsStandard of careTypes of tumorsPrognostic factorsTreatment of cancerPatient populationTreatment decisionsCognitive deteriorationLocal controlMetastasisPatientsPrognosisRadiotherapyTherapy